67.85 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||68.08 x 1400|
|Ask||68.09 x 800|
|Day's Range||67.80 - 71.89|
|52 Week Range||43.27 - 86.58|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||23.90|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.87|
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the final study results from the Phase 3 APPROACH study evaluating WAYLIVRA® (volanesorsen) in patients with familial chylomicronemia syndrome (FCS) were published in the August 8th issue of The New England Journal of Medicine (NEJM). It is caused by impaired production or function of the enzyme, lipoprotein lipase (LPL), responsible for breaking down chylomicrons, lipoproteins rich in triglycerides. WAYLIVRA is designed to reduce the production of apolipoprotein C-III (apoC-III), a protein produced in the liver that plays a central role in the regulation of plasma triglycerides.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 96.30% and 16.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) Allakos Inc (NASDAQ: ALLK )(announced common stock offering) ...
Q2 2019 year-to-date revenues increased more than 75% to $461 million SPINRAZA sales surpass $1 billion in the first half of 2019 Ionis on track for third consecutive year of net income Conference call ...
Achieved Second Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $10 Million Conference Call Webcast Tuesday, August 6, 4:30 p.m. ET at www.akceatx.com BOSTON,.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today topline results from the BROADEN study in patients with familial partial lipodystrophy (FPL). The study met its primary endpoint demonstrating a statistically significant reduction in triglyceride levels in patients with FPL treated with WAYLIVRA compared to placebo-treated patients. In addition to achieving the primary endpoint, the study achieved an important secondary endpoint of a statistically significant reduction in liver fat.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARLSBAD, Calif., July 30, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Wednesday, August 7th at 11:30 a.m. Eastern Time to discuss its second quarter 2019 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.
Chairman & CEO of Ionis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stanley T Crooke (insider trades) sold 10,000 shares of IONS on 07/18/2019 at an average price of $70.25 a share. Continue reading...
John McCamant, editor of The Medical Technology Stock Letter, selected Ionis Pharmaceuticals (IONS) as a more conservative idea idea for 2019. The stock has risen 21%. Here's his latest update on this biotech firm.
- New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including ...
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
Biogen (BIIB) today announced an update to the European label for nusinersen, incorporating longer-term data from four studies (NURTURE, EMBRACE, SHINE and CS3A). No new safety concerns were identified.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
BOSTON and CARLSBAD, Calif., June 20, 2019 -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:.
Ionis Pharmaceuticals Inc NASDAQ/NGS:IONSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IONS are favorable, with net inflows of $3.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.